非酒精性脂肪性肝炎生物标誌物市场规模,份额和趋势分析报告：按类型（血清,肝纤维化,细胞凋亡,氧化应激）,用户（製药和CRO,医院）,地区预测2022-2030

非酒精性脂肪性肝炎生物标誌物的市场增长和趋势

根据 Grand View Research, Inc. 的最新报告，到 2030 年，全球非酒精性脂肪性肝炎生物标誌物市场规模预计将达到 54 亿美元，预测期内的复合年增长率为 23.6%。非酒精性脂肪性肝炎 (NASH) 生物标誌物市场的增长归因于慢性病患病率上升以及对提供新诊断工具的需求不断增加。非酒精性脂肪性肝炎 (NAFLD) 在患有某些疾病（如肥胖）或被认为与肥胖相关的疾病（如 2 型糖尿病）的人群中更为常见。据估计，三分之一到三分之二的 2 型糖尿病患者患有 NAFLD。

根据美国国立卫生研究院 2021 年 4 月的一项研究，高达 75% 的超重人群和超过 90% 的极度肥胖人群患有 NAFLD。越来越多的肥胖人口和不健康的饮食习惯为肝病的发展创造了有利的环境。因此，慢性肝病患病率的上升预计将刺激对 NASH 生物标誌物的需求。这一领域的持续研究活动可能会维持市场增长。

增长的一个主要驱动力是非酒精性脂肪性肝炎等慢性肝病发病率的增加以及开发早期检测和诊断方法的需要。儘管缺乏用于诊断 NAFLD 的单一可靠的非侵入性程序，但非酒精性脂肪性肝炎生物标誌物市场具有显着的增长潜力。另一个增长因素是对非侵入性诊断方法的需求不断增长。由于其他诊断方法具有侵入性且价格昂贵，因此不适合患者使用。

此外，市场上的主要参与者正在专注于旨在提高公众意识的合作伙伴关係，进一步促进市场的增长。例如，2022 年 6 月，Echosens 和诺和诺德宣布建立合作伙伴关係，以提高对 NASH 的认识，并加快 Echosens 的 FibroScan 系统等非侵入性筛查方法的采用率。该伙伴关係的目标是到 2025 年将严重和晚期 NASH 的诊断率提高一倍。

诊断 NASH 的高成本是製约该市场增长的主要因素。例如，用于监测和诊断 NASH 的肝活检是一种侵入性且昂贵的手术，费用高达 3500 美元。此外，FDA 等监管机构对生物标誌物的批准有严格的规定，这阻碍了行业的扩张。

非酒精性脂肪性肝炎生物标誌物市场报告要点

按类型划分，血清生物标誌物领域在 NASH 生物标誌物市场中占有最大份额，因为血清生物标誌物是最有效且使用最广泛的诊断工具。

在终端用户方面，由于对诊断肝病的非侵入性工具的高需求，预计製药和 CRO 行业在预测期内增长最快

由于传染病、心血管疾病和癌症的患病率上升，2021 年全球市场以北美为主

市场上的主要参与者正专注于专注于早期诊断的协作研究和合作伙伴关係，并提高人们对存在用于确定 NAFLD 和 NASH 的诊断工具的认识

Contents

第 1 章 NASH 生物标誌物市场：研究方法和范围

• 调查方法
• 调查假设
• 资讯采购
  • 购买的数据库
  • GVR 内部数据库
  • 次要资讯
  • 初步调查
  • 初步调查的内容
• 资讯或数据分析
  • 数据分析模型
• 市场製定和验证
• 模型详细资讯
  • 商品流分析
    • 方法 1：商品流方法
  • 批量价格分析（模型 2）
    • 方法 2：体积分析
    • 收入建模
• 二级资讯列表
• 主要资讯列表

第 2 章 NASH 生物标誌物市场：执行摘要

• 市场概览

第 3 章 NASH 生物标誌物市场：行业展望

• 市场系列展望
  • 母公司市场展望
• 描绘渗透率和增长前景
• 市场动态
  • 市场促进因素分析
    • 慢性肝病患病率上升
    • 对 NASH 生物标誌物的非侵入性诊断的需求不断增加
    • 政府和私人组织增加对 NASH 生物标誌物疗法研发的投资
  • 市场抑制因素分析
    • 与 NASH 药物相关的副作用和风险
• 波特的五力分析
• SWOT 因素分析（政治和法律、经济、技术）
• 监管框架
• 管道分析

第 4 章 NASH 生物标誌物市场：竞争格局

• 主要市场进入者的近期趋势和影响分析
  • Ansoff Matrix
• Major deals &strategic alliances analysis
  • 合资企业
  • 许可和合作伙伴关係
  • 技术合作
• 公司/竞争对手分类
• 供应商情况
  • 主要分销商和渠道合作伙伴列表
  • 主要客户
• 上市公司
  • 公司市场分析
• 私人公司
  • 主要初创企业名单
  • 本地网络地图

第 5 章 NASH 生物标誌物市场：类型业务分析

• 定义和范围
• 2021 年和 2030 年类型市场份额分析
• 全球 NASH 生物标誌物市场，按类型划分，2018-2030 年
• 2018-2030 年市场规模和预测、趋势分析
  • 血清生物标誌物
  • 肝纤维化生物标誌物
  • 细胞凋亡生物标誌物
  • 氧化应激生物标誌物
  • 其他

第 6 章 NASH 生物标誌物市场：最终用途业务分析

• 定义和范围
• 2021 年和 2030 年终端用途市场份额分析
• 全球 NASH 生物标誌物市场，按最终用途分类，2018-2030 年
• 2018-2030 年市场规模和预测、趋势分析
  • 製药和 CRO 行业
  • 医院
  • 诊断实验室
  • 学术研究机构

第 7 章 NASH 生物标誌物市场：区域业务分析

• 定义和范围
• 2021 年和 2030 年区域市场份额分析
• 区域市场仪表板
• 区域市场概况
• SWOT 分析，按因素（政治和法律、经济和技术）
  • 北美
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 多边环境协定
• 2021-2030 年市场规模、预测、趋势分析
• 北美
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 法国
  • 意大利
  • 西班牙
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳大利亚
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 多边环境协定
  • 南非
  • 沙特阿拉伯
  • 阿拉伯联合酋长国

第 8 章 NASH 生物标誌物市场：公司概况

• 公司简介
  • GENFIT
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Prometheus Laboratories
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • AstraZeneca
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Siemens Medical Solutions USA, Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Bristol-Myers Squibb Company
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • BioPredictive
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Quest Diagnostics
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Exalenz Bioscience Ltd
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Pfizer, Inc.
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措
  • Laboratory Corporation of America Holdings
    • 公司简介
    • 财务业绩
    • 产品基准
    • 战略举措

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends:

The global non-alcoholic steatohepatitis biomarkers market size is expected to reach USD 5.4 billion by 2030, registering a CAGR of 23.6% during the forecast period, according to a new report by Grand View Research, Inc. The growth of the Non-alcoholic Steatohepatitis (NASH) biomarkers market is attributed to rising prevalence of chronic diseases and rising demand for providing novel diagnostic tools. Nonalcoholic Fatty Liver Disease (NAFLD) is more prevalent in people with specific diseases, such as obesity, and diseases that may be linked to obesity, including type 2 diabetes. One-third to two-thirds of people with type 2 diabetes are projected to have NAFLD.

According to April 2021 study by NIH, up to 75% of overweight individuals and more than 90% of individuals with extreme obesity have NAFLD. An increasing obese population and unhealthy food habits are creating a favorable environment for the development of liver disease. Therefore, the rising prevalence of chronic liver disease is expected to fuel the demand for NASH biomarkers. The ongoing research activities in this sector are likely to sustain the market growth.

The primary factor pertaining to growth is the increasing incidence of chronic liver illnesses like nonalcoholic steatohepatitis and the need to develop ways for their early detection and diagnosis. The market for non-alcoholic steatohepatitis biomarkers has enormous growth potential despite the lack of a single reliable non-invasive procedure to diagnose NAFLD. Another growth factor is the increasing demand for non-invasive diagnosis methods as other diagnostic procedures available are intrusive and expensive, thus they are not suitable for patients.

Moreover, major key players operating in the market are focusing on collaborations aiming toward expanding awareness among the population is further propelling the growth of market. For instance, in June 2022, Echosens and Novo Nordisk announced a partnership to increase awareness about NASH and accelerate the adoption rate of noninvasive screening methods such as Echosens' FibroScan system. The partnership strives to double the diagnosis rate of severe and advanced NASH by 2025.

The high cost of diagnosing NASH is a significant factor hindering the growth of the market. For instance, liver biopsy for NASH for monitoring and diagnosis of the disease can cost up to USD 3500 making it an invasive and expensive procedure. Furthermore, regulatory authorities such as the FDA have strict rules for biomarker approval, which is slowing industry expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights:

• By type, the serum biomarkers segment held a larger share of the NASH biomarkers market since serum biomarkers are most effective and most widely used diagnosis tool

• By end-use, the pharma & CRO industry segment is expected to show the fastest growth over the forecast period due to the high demand for non-invasive tools for the diagnosis of liver diseases

• North America dominated the global market in 2021, owing to the rising prevalence of infectious diseases, cardiovascular diseases, and cancer

• Key players operating in the market are focusing on collaborations and partnerships focusing on expanding the awareness about early diagnosis and presence of diagnostic tools for determining NAFLD and NASH

Table of Contents

Chapter 1 NASH Biomarkers Market: Methodology and Scope

• 1.1 Research Methodology
• 1.2 Research Assumptions
  • 1.2.1 Estimates and forecast timeline
• 1.3 Information Procurement
  • 1.3.1 Purchased database
  • 1.3.2 GVR's internal database
  • 1.3.3 Secondary sources
  • 1.3.4 Primary research
  • 1.3.5 Details of primary research
• 1.4 Information or Data Analysis
  • 1.4.1 Data analysis models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity flow analysis
    • 1.6.1.1 Approach 1: Commodity flow approach
  • 1.6.2 Volume price analysis (model 2)
    • 1.6.2.1 Approach 2: Volume price analysis
    • 1.6.2.2 Revenue modeling
• 1.7 List of Secondary Sources
• 1.8 List of Primary Sources

Chapter 2 NASH Biomarkers Market: Executive Summary

• 2.1 Market Summary

Chapter 3 NASH Biomarkers Market: Industry Outlook

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration & Growth Prospect Mapping
• 3.3 Market Dynamics
  • 3.3.1 Market Driver Analysis
    • 3.3.1.1 Rising prevalence of chronic liver diseases
    • 3.3.1.2 Increasing demand for non-invasive diagnostics for NASH biomarkers
    • 3.3.1.3 Rising investment by government and private organizations in R&D for NASH biomarkers therapeutics
  • 3.3.2 Market Restraint Analysis
    • 3.3.2.1 Side-effects and risks associated with NASH therapeutics
• 3.4 Porter's Five Forces Analysis
• 3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
• 3.6 Regulatory Framework
• 3.7 Pipeline Analysis

Chapter 4 NASH Biomarkers Market: Competitive Landscape

• 4.1 Recent developments & impact analysis, by key market participants
  • 4.1.1 Ansoff Matrix
• 4.2 Major deals & strategic alliances analysis
  • 4.2.1 Joint Ventures
  • 4.2.2 Licensing and Partnerships
  • 4.2.3 Technological Collaborations
• 4.3 Company/Competition Categorization
• 4.4 Vendor Landscape
  • 4.4.1 List Of Key Distributors and Channel Partners
  • 4.4.2 Key Customers
• 4.5 Public Companies
  • 4.5.1 Company Market Position Analysis
• 4.6 Private Companies
  • 4.6.1 List Of Key Emerging Companies
  • 4.6.2 Regional Network Map

Chapter 5 NASH Biomarkers Market: Type Business Analysis

• 5.1 Definition and Scope
• 5.2 Type Market Share Analysis, 2021 & 2030
• 5.3 Global NASH Biomarkers Market, By Type, 2018 To 2030
• 5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 5.4.1 Serum Biomarkers
    • 5.4.1.1 Serum Biomarkers Market 2018 - 2030 (USD Million)
  • 5.4.2 Hepatic Fibrosis Biomarkers
    • 5.4.2.1 Hepatic Fibrosis Biomarkers Market, 2018 - 2030 (USD Million)
  • 5.4.3 Apoptosis Biomarkers
    • 5.4.3.1 Apoptosis Biomarkers Market, 2018 - 2030 (USD Million)
  • 5.4.4 Oxidative Stress Biomarkers
    • 5.4.4.1 Oxidative Stress Biomarkers Market, 2018 - 2030 (USD Million)
  • 5.4.5 Others
    • 5.4.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 NASH Biomarkers Market: End-Use Business Analysis

• 6.1 Definition and Scope
• 6.2 End-Use Market Share Analysis, 2021 & 2030
• 6.3 Global NASH Biomarkers Market, By End-Use, 2018 To 2030
• 6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
  • 6.4.1 Pharma & CRO Industry
    • 6.4.1.1 Pharma & CRO Industry Market 2018 - 2030 (USD Million)
  • 6.4.2 Hospitals
    • 6.4.2.1 Hospitals Market, 2018 - 2030 (USD Million)
  • 6.4.3 Diagnostic Labs
    • 6.4.3.1 Diagnostic Labs Market, 2018 - 2030 (USD Million)
  • 6.4.4 Academic Research Institutes
    • 6.4.4.1 Academic Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7 NASH Biomarkers Market: Regional Business Analysis

• 7.1 Definition & Scope
• 7.2 Regional Market Share Analysis, 2021 & 2030
• 7.3 Regional Market Dashboard
• 7.4 Regional Market Snapshot
• 7.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • 7.5.1 North America
  • 7.5.2 Europe
  • 7.5.3 Asia Pacific
  • 7.5.4 Latin America
  • 7.5.5 MEA
• 7.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
• 7.7 North America
  • 7.7.1 North America NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.7.2 U.S.
    • 7.7.2.1 U.S. NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.7.3 Canada
    • 7.7.3.1 Canada NASH Biomarkers Market, 2018 - 2030 (USD Million)
• 7.8 Europe
  • 7.8.1 Europe NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.2 U.K.
    • 7.8.2.1 U.K. NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.3 Germany
    • 7.8.3.1 Germany NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.4 France
    • 7.8.4.1 France NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.5 Italy
    • 7.8.5.1 Italy NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.8.6 Spain
    • 7.8.6.1 Spain NASH Biomarkers Market, 2018 - 2030 (USD Million)
• 7.9 Asia Pacific
  • 7.9.1 Asia Pacific NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.2 Japan
    • 7.9.2.1 Japan NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.3 China
    • 7.9.3.1 China NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.4 India
    • 7.9.4.1 India NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.5 Australia
    • 7.9.5.1 Australia NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.9.6 South Korea
    • 7.9.6.1 South Korea NASH Biomarkers Market, 2018 - 2030 (USD Million)
• 7.10 Latin America
  • 7.10.1 Latin America NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.10.2 Brazil
    • 7.10.2.1 Brazil NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.10.3 Mexico
    • 7.10.3.1 Mexico NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.10.4 Argentina
    • 7.10.4.1 Argentina NASH Biomarkers Market, 2018 - 2030 (USD Million)
• 7.11 MEA
  • 7.11.1 MEA NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.11.2 South Africa
    • 7.11.2.1 South Africa NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.11.3 Saudi Arabia
    • 7.11.3.1 Saudi Arabia NASH Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.11.4 UAE
    • 7.11.4.1 UAE NASH Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 8 NASH Biomarkers Market: Company Profiling

• 8.1 Company Profiles
  • 8.1.1. GENFIT
    • 8.1.1.1 Company overview
    • 8.1.1.2 Financial performance
    • 8.1.1.3 Product benchmarking
    • 8.1.1.4 Strategic initiatives
  • 8.1.2. Prometheus Laboratories
    • 8.1.2.1 Company overview
    • 8.1.2.2 Financial performance
    • 8.1.2.3 Product benchmarking
    • 8.1.2.4 Strategic initiatives
  • 8.1.3. AstraZeneca
    • 8.1.3.1 Company overview
    • 8.1.3.2 Financial performance
    • 8.1.3.3 Product benchmarking
    • 8.1.3.4 Strategic initiatives
  • 8.1.4. Siemens Medical Solutions USA, Inc.
    • 8.1.4.1 Company overview
    • 8.1.4.2 Financial performance
    • 8.1.4.3 Product benchmarking
    • 8.1.4.4 Strategic initiatives
  • 8.1.5. Bristol-Myers Squibb Company
    • 8.1.5.1 Company overview
    • 8.1.5.2 Financial performance
    • 8.1.5.3 Product benchmarking
    • 8.1.5.4 Strategic initiatives
  • 8.1.6. BioPredictive
    • 8.1.6.1 Company overview
    • 8.1.6.2 Financial performance
    • 8.1.6.3 Product benchmarking
    • 8.1.6.4 Strategic initiatives
  • 8.1.7. Quest Diagnostics
    • 8.1.7.1 Company overview
    • 8.1.7.2 Financial performance
    • 8.1.7.3 Product benchmarking
    • 8.1.7.4 Strategic initiatives
  • 8.1.8 Exalenz Bioscience Ltd
    • 8.1.8.1 Company overview
    • 8.1.8.2 Financial performance
    • 8.1.8.3 Product benchmarking
    • 8.1.8.4 Strategic initiatives
  • 8.1.9 Pfizer, Inc.
    • 8.1.9.1 Company overview
    • 8.1.9.2 Financial performance
    • 8.1.9.3 Product benchmarking
    • 8.1.9.4 Strategic initiatives
  • 8.1.10 Laboratory Corporation of America Holdings
    • 8.1.10.1 Company overview
    • 8.1.10.2 Financial performance
    • 8.1.10.3 Product benchmarking
    • 8.1.10.4 Strategic initiatives

List of Tables

• TABLE 1 List of Secondary Sources
• TABLE 2 List of Abbreviations
• TABLE 3 Regulatory Framework
• TABLE 4 Global NASH Biomarkers Market, By Region, 2018 - 2030 (USD Million)
• TABLE 5 Global NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 6 Global NASH Biomarkers Market, By End-use, 2018 - 2030 (USD Million)
• TABLE 7 North America NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 8 North America NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 9 North America NASH Biomarkers Market, By End-use, 2018 - 2030 (USD Million)
• TABLE 10 U.S. NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 11 U.S. NASH Biomarkers Market, By End-use, 2018 - 2030 (USD Million)
• TABLE 12 Canada NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 13 Canada NASH Biomarkers Market, By End-use, 2018 - 2030 (USD Million)
• TABLE 14 Europe NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 15 Europe NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 16 Europe NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 17 U.K. NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 18 U.K. NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 19 Germany NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 20 Germany NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 21 France NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 22 France NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 23 Spain NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 24 Spain NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 25 Italy NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 26 Italy NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 27 Asia Pacific NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 28 Asia Pacific NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 29 Asia Pacific NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 30 China NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 31 China NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 32 Japan NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 33 Japan NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 34 India NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 35 India NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 36 South Korea NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 37 South Korea NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 38 Australia NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 39 Australia NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 40 Latin America NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 41 Latin America NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 42 Latin America NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 43 Brazil NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 44 Brazil NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 45 Mexico NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 46 Mexico NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 47 Argentina NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 48 Argentina NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 49 MEA NASH Biomarkers Market, By Country, 2018 - 2030 (USD Million)
• TABLE 50 MEA NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 51 MEA NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 52 South Africa NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 53 South Africa NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 54 Saudi Arabia NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 55 Saudi Arabia NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)
• TABLE 56 UAE NASH Biomarkers Market, By Type, 2018 - 2030 (USD Million)
• TABLE 57 UAE NASH Biomarkers Market, By End-Use, 2018 - 2030 (USD Million)

List of Figures

• FIG. 1 Market Research Process
• FIG. 2 Information Procurement
• FIG. 3 Primary Research Pattern
• FIG. 4 Market Research Approaches
• FIG. 5 Value Chain-Based Sizing & Forecasting
• FIG. 6 Market Formulation & Validation
• FIG. 7 NASH Biomarkers Market Segmentation
• FIG. 8 Market Driver Relevance Analysis (Current & Future Impact)
• FIG. 9 Market Restraint Relevance Analysis (Current & Future Impact)
• FIG. 10 Market Challenge Relevance Analysis (Current & Future Impact)
• FIG. 11 Penetration & Growth Prospect Mapping
• FIG. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
• FIG. 13 Porter's Five Forces Analysis
• FIG. 14 Market Penetration & Growth Prospect Mapping
• FIG. 15 NASH Biomarkers Market: Type Movement Analysis
• FIG. 16 Serum biomarkers market, 2018 - 2030 (USD Million)
• FIG. 17 Hepatic fibrosis biomarkers market, 2018 - 2030 (USD Million)
• FIG. 18 Apoptosis biomarkers market, 2018 - 2030 (USD Million)
• FIG. 19 Oxidative stress biomarkers market, 2018 - 2030 (USD Million)
• FIG. 20 Others market, 2018 - 2030 (USD Million)
• FIG. 21 NASH Biomarkers Market: End-use Movement Analysis
• FIG. 22 Pharma & CRO Industry market, 2018 - 2030 (USD Million)
• FIG. 23 Hospitals market, 2018 - 2030 (USD Million)
• FIG. 24 Diagnostic Labs market, 2018 - 2030 (USD Million)
• FIG. 25 Academic Research Institutes market, 2018 - 2030 (USD Million)
• FIG. 26 Regional Marketplace: Key Takeaways
• FIG. 27 Regional Outlook, 2018 & 2030
• FIG. 28 Regional Market Dashboard
• FIG. 29 Regional Market Place: Key Takeaways
• FIG. 30 North America, SWOT Analysis
• FIG. 31 Europe, SWOT Analysis
• FIG. 32 Asia Pacific, SWOT Analysis
• FIG. 33 Latin America, SWOT Analysis
• FIG. 34 MEA, SWOT Analysis
• FIG. 35 North America
• FIG. 36 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 37 U.S.
• FIG. 38 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 39 Canada
• FIG. 40 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 41 Europe
• FIG. 42 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 43 UK
• FIG. 44 UK Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 45 Germany
• FIG. 46 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 47 France
• FIG. 48 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 49 Italy
• FIG. 50 Italy Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 51 Spain
• FIG. 52 Spain Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 53 Asia Pacific
• FIG. 54 Asia-Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 55 Japan
• FIG. 56 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 57 China
• FIG. 58 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 59 India
• FIG. 60 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 61 Australia
• FIG. 62 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 63 South Korea
• FIG. 64 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 65 Latin America
• FIG. 66 Latin America Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 67 Brazil
• FIG. 68 Brazil Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 69 Mexico
• FIG. 70 Mexico Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 71 Argentina
• FIG. 72 Argentina Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 73 MEA
• FIG. 74 MEA Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 75 South Africa
• FIG. 76 South Africa Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 77 Saudi Arabia
• FIG. 78 Saudi Arabia Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 79 UAE
• FIG. 80 UAE Market Estimates And Forecast, 2018 - 2030 (USD Million)
• FIG. 81 Strategy Mapping